IBRX vs SPY
Immunitybio Inc (IBRX) versus SPDR S&P 500 ETF Trust (SPY) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
SPDR S&P 500 ETF Trust (SPY) common stock listed on US.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
SPY does not have a complete income-statement cache yet.
IBRX currently screens at market cap $7.88B. SPY currently screens at market cap $0.
Not investment advice. Open the IBRX and SPY stock pages for the full models.
Not investment advice.